Targeting CDK4/6 in patients with cancer von Hamilton, Erika, Infante, Jeffrey R

Volltext

Molecular Pathways: Fatty Acid Synthase von Jones, Suzanne F, Infante, Jeffrey R

Volltext

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study von McDermott, David F, Sosman, Jeffrey A, Sznol, Mario, Massard, Christophe, Gordon, Michael S, Hamid, Omid, Powderly, John D, Infante, Jeffrey R, Fassò, Marcella, Wang, Yan V, Zou, Wei, Hegde, Priti S, Fine, Gregg D, Powles, Thomas

Volltext

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial von Patel, Manish R, Ellerton, John, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael, Aljumaily, Raid, Britten, Carolyn D, Dirix, Luc, Lee, Keun-Wook, Taylor, Mathew, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Gelb, Arnold B, Xiong, Junyuan, Rosen, Galit, Gulley, James L, Apolo, Andrea B

Volltext

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial von Infante, Jeffrey R, Dr, Fecher, Leslie A, MD, Falchook, Gerald S, MD, Nallapareddy, Sujatha, MD, Gordon, Michael S, MD, Becerra, Carlos, MD, DeMarini, Douglas J, PhD, Cox, Donna S, PhD, Xu, Yanmei, MS, Morris, Shannon R, MD, Peddareddigari, Vijay GR, MD, Le, Ngocdiep T, MD, Hart, Lowell, MD, Bendell, Johanna C, MD, Eckhardt, Gail, MD, Kurzrock, Razelle, Prof, Flaherty, Keith, MD, Burris, Howard A, MD, Messersmith, Wells A, MD

Volltext

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies von Shih, Kent, Arkenau, Hendrik-Tobias, Infante, Jeffrey R.

Volltext

Targeting PI3 kinase in cancer von Bauer, Todd M, Patel, Manish R, Infante, Jeffrey R

Volltext

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma von Courtney, Kevin D, Infante, Jeffrey R, Lam, Elaine T, Figlin, Robert A, Rini, Brian I, Brugarolas, James, Zojwalla, Naseem J, Lowe, Ann M, Wang, Keshi, Wallace, Eli M, Josey, John A, Choueiri, Toni K

Volltext

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study von Apolo, Andrea B, Infante, Jeffrey R, Balmanoukian, Ani, Patel, Manish R, Wang, Ding, Kelly, Karen, Mega, Anthony E, Britten, Carolyn D, Ravaud, Alain, Mita, Alain C, Safran, Howard, Stinchcombe, Thomas E, Srdanov, Marko, Gelb, Arnold B, Schlichting, Michael, Chin, Kevin, Gulley, James L

Volltext

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor von KIM, Kevin B, KEFFORD, Richard, GONZALEZ, Rene, OTT, Patrick A, LONG, Georgina V, GARDNER, Olivia S, OUELLET, Daniele, YANMEI XU, DEMARINI, Douglas J, LE, Ngocdiep T, PATEL, Kiran, LEWIS, Karl D, PAVLICK, Anna C, INFANTE, Jeffrey R, RIBAS, Antoni, SOSMAN, Jeffrey A, FECHER, Leslie A, MILLWARD, Michael, MCARTHUR, GrantA, HWU, Patrick

Volltext

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study von Horn, Leora, Infante, Jeffrey R, Reckamp, Karen L, Blumenschein, George R, Leal, Ticiana A, Waqar, Saiama N, Gitlitz, Barbara J, Sanborn, Rachel E, Whisenant, Jennifer G, Du, Liping, Neal, Joel W, Gockerman, Jon P, Dukart, Gary, Harrow, Kimberly, Liang, Chris, Gibbons, James J, Holzhausen, Allison, Lovly, Christine M, Wakelee, Heather A

Volltext

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma von Middleton, Mark R, McAlpine, Cheryl, Woodcock, Victoria K, Corrie, Pippa, Infante, Jeffrey R, Steven, Neil M, Evans, Thomas R Jeffry, Anthoney, Alan, Shoushtari, Alexander N, Hamid, Omid, Gupta, Avinash, Vardeu, Antonella, Leach, Emma, Naidoo, Revashnee, Stanhope, Sarah, Lewis, Sion, Hurst, Jacob, O'Kelly, Ita, Sznol, Mario

Volltext

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial von Falchook, Gerald S, Dr, Long, Georgina V, PhD, Kurzrock, Razelle, Prof, Kim, Kevin B, MD, Arkenau, Tobias H, PhD, Brown, Michael P, PhD, Hamid, Omid, MD, Infante, Jeffrey R, MD, Millward, Michael, MD, Pavlick, Anna C, MD, O’Day, Steven J, MD, Blackman, Samuel C, PhD, Curtis, C Martin, BA, Lebowitz, Peter, PhD, Ma, Bo, PhD, Ouellet, Daniele, PhD, Kefford, Richard F, Prof

Volltext

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors von Tabernero, Josep, Bahleda, Rastislav, Dienstmann, Rodrigo, Infante, Jeffrey R, Mita, Alain, Italiano, Antoine, Calvo, Emiliano, Moreno, Victor, Adamo, Barbara, Gazzah, Anas, Zhong, Bob, Platero, Suso J, Smit, Johan W, Stuyckens, Kim, Chatterjee-Kishore, Moitreyee, Rodon, Jordi, Peddareddigari, Vijay, Luo, Feng R, Soria, Jean-Charles

Volltext

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas von Infante, Jeffrey R, Cassier, Philippe A, Gerecitano, John F, Witteveen, Petronella O, Chugh, Rashmi, Ribrag, Vincent, Chakraborty, Abhijit, Matano, Alessandro, Dobson, Jason R, Crystal, Adam S, Parasuraman, Sudha, Shapiro, Geoffrey I

Volltext

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients von Sullivan, Ryan J., Hamid, Omid, Gonzalez, Rene, Infante, Jeffrey R., Patel, Manish R., Hodi, F. Stephen, Lewis, Karl D., Tawbi, Hussein A., Hernandez, Genevive, Wongchenko, Matthew J., Chang, YiMeng, Roberts, Louise, Ballinger, Marcus, Yan, Yibing, Cha, Edward, Hwu, Patrick

Volltext

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study von Hammers, Hans J, Plimack, Elizabeth R, Infante, Jeffrey R, Rini, Brian I, McDermott, David F, Lewis, Lionel D, Voss, Martin H, Sharma, Padmanee, Pal, Sumanta K, Razak, Albiruni R Abdul, Kollmannsberger, Christian, Heng, Daniel Y C, Spratlin, Jennifer, McHenry, M Brent, Amin, Asim

Volltext

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib von Long, Georgina V, Weber, Jeffrey S, Infante, Jeffrey R, Kim, Kevin B, Daud, Adil, Gonzalez, Rene, Sosman, Jeffrey A, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Kefford, Richard F, Lawrence, Donald, Kudchadkar, Ragini, Burris, 3rd, Howard A, Falchook, Gerald S, Algazi, Alain, Lewis, Karl, Puzanov, Igor, Ibrahim, Nageatte, Sun, Peng, Cunningham, Elizabeth, Kline, Amy S, Del Buono, Heather, McDowell, Diane Opatt, Patel, Kiran, Flaherty, Keith T

Volltext

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial von Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD

Volltext

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients von Naing, Aung, Infante, Jeffrey R., Papadopoulos, Kyriakos P., Chan, Ivan H., Shen, Cong, Ratti, Navneet P., Rojo, Bianca, Autio, Karen A., Wong, Deborah J., Patel, Manish R., Ott, Patrick A., Falchook, Gerald S., Pant, Shubham, Hung, Annie, Pekarek, Kara L., Wu, Victoria, Adamow, Matthew, McCauley, Scott, Mumm, John B., Wong, Phillip, Van Vlasselaer, Peter, Leveque, Joseph, Tannir, Nizar M., Oft, Martin

Volltext